Gilead Sciences Inc
GILDHealthcare|Drug Manufacturers - General|USA
$140.13
+0.42 (+0.30%)
DCF (FCF)
$82.91
Earnings Power
$67.72
Clinical Trials (539)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07210125 Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting | HIV | P4 | Active | 75 | Open-label | Lenacapavir long-acting |
| NCT06964113 A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice | Ulcerative Colitis | P4 | Recruiting | 94 | Open-label | Filgotinib Maleate |
| NCT05140941 Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy | Hepatitis C, Chronic, Pregnancy; Infection | P4 | Recruiting | 100 | Open-label | Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet |
| NCT06337032 A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments | HIV-1-infection | P4 | Recruiting | 350 | Open-label | F/TAF (High Dose Tablet), F/TAF (Low Dose Tablet), F/TAF (Lowest Dose Tablet), F/TAF (High Dose TOS), F/TAF (Low Dose TOS), F/TAF (Lowest Dose TOS), E/C/F/TAF, E/C/F/TAF (Low Dose), Cobicistat (High Dose), Cobicistat (Low Dose), Cobicistat (TOS), B/F/TAF (High Dose), B/F/TAF (Low Dose), B/F/TAF (High Dose TOS), B/F/TAF (Low Dose TOS), B/F/TAF (Lowest Dose TOS), 3rd ARV Agent, Nucleos(t)ide reverse transcriptase inhibitors (NRTI), ATV, DRV, Lopinavir Boosted with ritonavir (LPV/r) |
| NCT06374758 Accelerated ART Initiation for PWHIV Who Are Out of Care | HIV Infections, ART | P4 | Recruiting | 120 | Open-label | bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg |
| NCT07218211 Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP | HIV Prevention, HIV Pre-exposure Prophylaxis | P4 | Recruiting | 100 | Open-label | Lenacapavir long-acting |
| NCT05502237 Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer | Non-small Cell Lung Cancer | P3 | Active | 1,021 | RCT, Open-label | Zimberelimab, Domvanalimab, Pembrolizumab, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed |
| NCT05814432 Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS | Disseminated Histoplasma Capsulatum Infection, AIDS and Infections | P3 | Recruiting | 279 | RCT, Open-label | Single high dose of liposomal amphotericin B, L-AmB standard dose |
| NCT05568095 A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body | Advanced Upper Gastrointestinal Tract Adenocarcinoma | P3 | Active | 1,040 | RCT, Open-label | Domvanalimab, Zimberelimab, Capecitabine, Fluorouracil, Leucovorin, Oxaliplatin, Nivolumab |
| NCT05633654 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | Triple Negative Breast Cancer | P3 | Recruiting | 1,514 | RCT, Open-label | Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine |
| NCT06413498 A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma | Multiple Myeloma | P3 | Recruiting | 450 | RCT, Open-label | Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib |
| NCT04925752 Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection | Pre-Exposure Prophylaxis of HIV Infection | P3 | Active | 3,292 | RCT, Double-blind | Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only) |
| NCT05605899 Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma | High-risk Large B-cell Lymphoma (LBCL) | P3 | Recruiting | 300 | RCT, Open-label | Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Etoposide, Rituximab, Doxorubicin, Vincristine, Prednisone |
| NCT04150068 Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance | HIV-1-infection | P2P3 | Active | 72 | RCT, Double-blind | Oral Lenacapavir, Oral Lenacapavir Placebo, Subcutaneous Lenacapavir, Failing ARV Regimen, Optimized Background Regimen (OBR) |
| NCT06486441 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) | Endometrial Cancer | P3 | Active | 640 | RCT, Open-label | Sacituzumab govitecan-hziy, Doxorubicin, Paclitaxel |
| NCT06532656 Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1 | HIV-1-infection | P2P3 | Recruiting | 75 | Open-label | Lenacapavir, BIC/LEN FDC |
| NCT06081244 NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) | Triple Negative Breast Cancer | P3 | Recruiting | 348 | RCT, Open-label | Sacituzumab govitecan, Pembrolizumab |
| NCT04595565 Sacituzumab Govitecan in Primary HER2-negative Breast Cancer | HER2-negative Breast Cancer, Triple Negative Breast Cancer | P3 | Active | 1,332 | RCT, Open-label | Capecitabine, Carboplatin, Cisplatin, Sacituzumab govitecan |
| NCT05502341 Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen | HIV-1-infection | P2P3 | Active | 689 | RCT, Open-label | Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen |
| NCT05378399 SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder | HIV Infections, Substance Use | P3 | Recruiting | 40 | Open-label | Descovy or Truvada |
| NCT02842086 Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection | Pre-Exposure Prophylaxis of HIV-1 Infection | P3 | Active | 5,399 | RCT, Double-blind | F/TAF, F/TDF, F/TAF Placebo, F/TDF Placebo |
| NCT02914535 Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis | Ulcerative Colitis | P3 | Active | 1,173 | Double-blind | Filgotinib, Placebo |
| NCT05609968 Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) | Carcinoma, Non-Small-Cell Lung | P3 | Active | 614 | RCT, Open-label | Sacituzumab Govitecan, Pembrolizumab |
| NCT05371093 Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Follicular Lymphoma | P3 | Active | 231 | RCT, Open-label | Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Lenalidomide, Rituximab, Doxorubicin, Vincristine, Prednisone, Bendamustine |
| NCT05552001 Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer | Triple Negative Breast Cancer, Metastatic Breast Cancer | P3 | Recruiting | 96 | Open-label | Sacituzumab govitecan |
| NCT04736173 Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer | Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer | P2 | Active | 169 | RCT, Open-label | Domvanalimab, Zimberelimab, Carboplatin, Paclitaxel, Pemetrexed, Pembrolizumab |
| NCT06727565 Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 | Head and Neck Squamous Cell Carcinoma | P2 | Active | 100 | RCT, Open-label | Domvanalimab, Zimberelimab, Paclitaxel, Carboplatin |
| NCT05676931 Study With Various Immunotherapy Treatments in Participants With Lung Cancer | Advanced Non-Small Cell Lung Cancer | P2 | Active | 400 | RCT, Open-label | Domvanalimab, Quemliclustat, Zimberelimab, Docetaxel, Platinum-Based Doublet |
| NCT05633667 Study of Novel Treatment Combinations in Patients With Lung Cancer | Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer | P2 | Recruiting | 270 | RCT, Open-label | Zimberelimab (ZIM), Domvanalimab (DOM), Sacituzumab govitecan-hziy (SG), Etrumadenant (ETRUMA), Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Docetaxel, Nivolumab |
| NCT06048133 Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) | Biliary Tract Carcinoma, Cholangiocarcinoma | P2 | Recruiting | 33 | Open-label | Gemcitabine, Cisplatin, Zimberelimab, Quemliclustat |
| NCT05396885 Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1) | Multiple Myeloma | P2 | Active | 136 | Open-label | anitocabtagene-autoleucel |
| NCT04986579 Scalp Cooling in MBC | Metastatic Breast Cancer, Chemotherapy-induced Alopecia | P2 | Recruiting | 120 | Open-label | Eribulin, Sacituzumab govitecan, Trastuzumab deruxtecan |
| NCT06631365 PrEPsmart 2-1-1 Pilot | HIV-1-infection | P2 | Recruiting | 60 | RCT, Open-label | Truvada |
| NCT05329766 A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies | Gastrointestinal Tract Malignancies | P2 | Active | 332 | RCT, Open-label | Domvanalimab, Quemliclustat, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin |
| NCT05327530 A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) | Locally Advanced or Metastatic Urothelial Carcinoma | P2 | Active | 256 | RCT, Open-label | Avelumab, Sacituzumab Govitecan, M6223, NKTR-255 |
| NCT07063212 A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) | Squamous Cell Carcinoma of Head and Neck, Sinus Cancer | P2 | Recruiting | 40 | Open-label | Sacituzumab Govitecan, Cetuximab |
| NCT03964727 Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors | Metastatic Solid Tumor | P2 | Active | 223 | Open-label | Sacituzumab Govitecan-hziy |
| NCT06029972 Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | P2 | Recruiting | 176 | RCT, Double-blind | Tilpisertib Fosmecarbil, Placebo |
| NCT05884320 Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers | Gland, Salivary Gland Cancers | P2 | Recruiting | 30 | RCT, Open-label | Sacituzumab Govitecan |
| NCT06100874 A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) | Her 2 Positive Breast Cancer, Breast Cancer Female | P2 | Active | 28 | Open-label | Sacituzumab Govitecan, Trastuzumab, Trastuzumab and Hyaluronidase-oysk |
| NCT05119907 Study of Sacituzumab Govitecan in Patients With Solid Tumor | Solid Tumor | P2 | Active | 53 | Open-label | Sacituzumab Govitecan-hziy |
| NCT06329869 Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | P2 | Recruiting | 35 | Open-label | Sacituzumab govitecan |
| NCT06248515 A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors | Thymoma, Thymic Carcinoma | P2 | Recruiting | 18 | Open-label | Sacituzumab govitecan-hziy |
| NCT04251416 A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma | Endometrial Carcinoma | P2 | Active | 50 | Open-label | Sacituzumab Govitecan |
| NCT06101329 Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102) | Pre-Exposure Prophylaxis of HIV Infection | P2 | Active | 253 | RCT, Open-label | Lenacapavir Tablet, Lenacapavir Injection, Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) |
| NCT05101096 Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors | Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer | P1P2 | Active | 135 | Open-label | Sacituzumab Govitecan-hziy |
| NCT02932150 Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection | Chronic Hepatitis B | P2 | Recruiting | 150 | RCT, Double-blind | TAF, Placebo |
| NCT06028932 A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients | Ovarian Carcinoma | P2 | Active | 20 | Open-label | Sacituzumab govitecan |
| NCT03424005 A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | Metastatic Breast Cancer | P1P2 | Recruiting | 792 | RCT, Open-label | Capecitabine, Atezolizumab, Ipatasertib, SGN-LIV1A, Bevacizumab, Chemotherapy (Gemcitabine + Carboplatin or Eribulin), Selicrelumab, Tocilizumab, Nab-Paclitaxel, Sacituzumab Govitecan, Abemaciclib, Fulvestrant, Ribociclib (Dose #1), Inavolisib (Dose #1), Trastuzumab Deruxtecan, Ribociclib (Dose #2), Letrozole, Inavolisib (Dose #2), Inavolisib, Empagliflozin, Palbociclib, Metformin, Atirmociclib |
| NCT06401824 Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases | NSCLC Stage IV, Brain Metastases, Adult | P2 | Recruiting | 25 | Open-label | Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab |
| NCT06926920 A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer | Triple Negative Breast Cancer | P1P2 | Recruiting | 100 | Open-label | Sacituzumab Govitecan-hziy (SG) |
| NCT06250036 Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer | Locally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer | P2 | Recruiting | 50 | RCT, Open-label | Single agent zimberelimab, Combination zimberelimab + domvanalimab |
| NCT06235216 Sacituzumab govitEcan in THYroid Cancers | Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer | P2 | Recruiting | 42 | Open-label | Sacituzumab govitecan |
| NCT06665178 Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer | Breast Cancer | P2 | Recruiting | 20 | Open-label | Sacituzumab Govitecan |
| NCT05833867 Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer | Localized Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma | P1 | Recruiting | 20 | Open-label | Sacituzumab govitecan |
| NCT04155749 Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma | Relapsed and Refractory Multiple Myeloma | P1 | Active | 40 | Open-label | anitocabtagene-autoleucel |
| NCT06079164 Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma | Relapsed/Refractory Large B-cell Lymphoma | P1 | Active | 39 | Open-label | KITE-197, Cyclophosphamide, Fludarabine |
| NCT04617522 Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment | Advanced or Metastatic Solid Tumor, Liver Failure | P1 | Recruiting | 30 | Open-label | Sacituzumab Govitecan-hziy |
| NCT06065371 Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | Gastrointestinal Cancer | P1 | Recruiting | 20 | Open-label | Capecitabine, Sacituzumab govetican |
| NCT06031415 Study of GS-0272 in Participants With Rheumatoid Arthritis | Rheumatoid Arthritis | P1 | Active | 55 | RCT, Double-blind | GS-0272, Placebo |
| NCT05143229 Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer | Breast Cancer | P1 | Active | 18 | Open-label | Alpelisib, Sacituzumab govitecan |
| NCT03275311 Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008 | Metastatic Breast Cancer | Recruiting | 40,000 | — | — | |
| NCT03577197 Southeast Netherlands Advanced Metastatic Breast Cancer Registry | Advanced Breast Cancer, Metastatic Breast Cancer | Recruiting | 7,000 | — | — | |
| NCT00404989 Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People. | HIV Infections, Hepatitis B | Recruiting | 24,258 | — | — | |
| NCT03112044 Lung Transplant HCV, Pilot Study | Lung Transplant Infection, Hepatitis C | Early P1 | Active | 26 | Open-label | Sofosbuvir-velpatasvir (400 mg/100 mg) |
| NCT05349227 Comprehensive Outcomes for After Cancer Health | Ovarian Cancer, Breast Cancer | N/A | Recruiting | 625 | RCT, Open-label | — |
| NCT06889805 HDV Screening Study | Hepatitis D Virus Infection | Recruiting | 300 | — | — | |
| NCT06774027 Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer | HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma | Recruiting | 100 | — | Non-Investigational Antibody-Drug Conjugates (ADC) | |
| NCT06717581 Variation in Drug Interactions in People With HIV (PLWH) Aged 60 Years and Older. | HIV Infections, Drug Interaction | Recruiting | 50 | — | — | |
| NCT07357038 A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for br- IFD(Breakthrough Invasive Fungal Disease) in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins Prophylaxis | Fungal Disease | Recruiting | 38 | — | Patients received the Drug: liposomal amphotericin B（AmBisome） for treatment | |
| NCT04453436 HIV Drug Resistance Among Individuals Failing Tenofovir/Lamivudine and Dolutegravir First Line Regimen in Brazil | HIV, Drug | Active | 2,500 | — | Tenofovir Disoproxil | |
| NCT05467930 CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2 | COVID-19, SARS CoV 2 Infection | Recruiting | 1,000 | — | — | |
| NCT05350865 Thailand HDV Cohort | HDV | Recruiting | 3,152 | — | — | |
| NCT05866523 Teamwork Makes the Dream Work | HIV Infections, Inpatient Facility Diagnoses | N/A | Recruiting | 250 | Open-label | — |
| NCT06353295 Community-based, Peer-delivered PrEP for Female Sex Workers in Rural Uganda: The Peers for PrEP (P4P) Study | HIV/AIDS | N/A | Active | 140 | Open-label | — |
| NCT05688592 Usefulness of PET-CT for Invasive Fungal Infection | Invasive Fungal Infections | Recruiting | 224 | — | — | |
| NCT03044964 Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR) | Angina | P4 | Unknown | 40 | RCT, Double-blind | Ranolazine, Placebo |
| NCT02691728 Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease | Chronic Hepatitis C | P4 | Unknown | 40 | Open-label | LDV/SOF FDC |
| NCT01641367 A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure | HIV-1 Infection | P4 | Completed | 545 | RCT, Open-label | Darunavir, Etravirine, Emtricitabine/tenofovir disoproxil fumarate, Raltegravir, Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs), Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available |
| NCT02800655 Digital Health Feedback System for Longitudinal Measurement of Medication Adherence During Anti-Retroviral (ARV)Therapy | HIV | P4 | Unknown | 100 | Open-label | — |
| NCT07476339 REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE | HIV -1 Infection, HIV (Human Immunodeficiency Virus) | P4 | Not Yet Recruiting | 200 | Open-label | Bictegravir, emtricitabine, and tenofovir alafenamide |
| NCT03502005 Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1 | Human Immunodeficiency Virus | P4 | Completed | 100 | Open-label | bictegravir/emtricitabine/tenofovir alafenamide |
| NCT01761643 CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM | Patient Adherence, HIV Seronegativity | P4 | Completed | 398 | RCT, Open-label | — |
| NCT00362544 PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia | Leukemia | P4 | Completed | 30 | Open-label | Ambisome |
| NCT00736190 A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults With Chronic Hepatitis B Infection | Chronic Hepatitis B | P4 | Completed | 90 | Open-label | Tenofovir disoproxil fumarate |
| NCT02081469 Prophylaxis of CHB Patients With Malignant Tumor Receiving Chemotherapy | Hepatitis B, Chronic, Tumor | P4 | Completed | 100 | RCT, Single-blind | — |
| NCT04319198 Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy | Metastatic Solid Tumors | P4 | Completed | 25 | Open-label | Sacituzumab Govitecan-hiy |
| NCT03549312 Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy | HIV-1-infection, Hepatitis C, Chronic | P4 | Unknown | 25 | Open-label | Genvoya, Epclusa, Biktarvy |
| NCT02423265 Efficacy of Ranolazine in Patients With Chronic Total Occlusions of Coronary Arteries | Myocardial Ischemia, Coronary Artery Disease | P4 | Withdrawn | — | RCT, Double-blind | Ranolazine, Placebo |
| NCT00224458 Combination of Efavirenz and Truvada - COMET Study | HIV Infections | P4 | Completed | 400 | Open-label | Truvada, efavirenz |
| NCT00617305 Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1) | Pulmonary Arterial Hypertension | P4 | Completed | 38 | RCT, Double-blind | Ambrisentan, Placebo, Sildenafil, Tadalafil |
| NCT00444379 Anti-Retrovirals for Kaposi's Sarcoma | Kaposi's Sarcoma, HIV Infections | P4 | Completed | 224 | RCT, Single-blind | Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir |
| NCT04965662 The Role of Home Packs of HIV PEPSE in High Risk Individuals | HIV-1-infection | P4 | Completed | 139 | RCT, Open-label | Maraviroc, Truvada |
| NCT03987503 The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study | Hepatitis C, Chronic | P4 | Completed | 87 | Open-label | Epclusa (SOF/VEL), Standard of care |
| NCT05147740 Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of Age | HIV-1-infection | P4 | Unknown | 50 | Open-label | B/F/TAF |
| NCT00867048 Strategic Timing of Antiretroviral Treatment | HIV Infection | P4 | Completed | 4,688 | RCT, Open-label | All licensed antiretroviral medications |
| NCT02739360 Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820 | Lymphoid Malignancies | P4 | Terminated | 3 | Open-label | Idelalisib |
| NCT00643968 Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial | HIV Infections | P4 | Completed | 140 | RCT, Open-label | EFV+TDF, EFV+3TC+TDF |
| NCT00334412 COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis | Invasive Aspergillosis | P4 | Completed | 30 | RCT, Open-label | Ambisome, caspofungin |
| NCT03120494 Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B | HIV/AIDS | P4 | Unknown | 75 | Open-label | Emtricitabine and Tenofovir |
| NCT00960622 Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects | HIV | P4 | Completed | 17 | RCT, Open-label | Truvada, Combivir, Trizivir |
| NCT01435174 Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients | End-stage Renal Disease, Cardiovascular Disease | P4 | Completed | 17 | Open-label | Ranolazine |
| NCT04551573 A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects | Tuberculosis, Hiv | P4 | Withdrawn | — | RCT, Open-label | Rifapentine daily, Rifapentine weekly |
| NCT02638233 Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy | Chronic Hepatitis C | P4 | Unknown | 40 | Open-label | Sofosbuvir 400mg / Ledipasvir 90 mg (FDC) |
| NCT03471624 Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF) | Hepatitis B, Chronic | P4 | Completed | 270 | Open-label | Tenofovir Alafenamide |
| NCT03158116 The Use of Inhaled Aztreonam in Children With a Tracheostomy Tube and Pseudomonas | Tracheostomy Infection | P4 | Terminated | 5 | Open-label | Inhaled Aztreonam |
| NCT01721967 Ranolazine for the Treatment of Chest Pain in HCM Patients | Hypertrophic Cardiomyopathy | P4 | Completed | 14 | Open-label | Ranolazine |
| NCT02547844 Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla | HIV-1 | P4 | Completed | 30 | RCT, Open-label | efavirenz + emtricitabina + tenofovir, rilpivirina + emtricitabina + tenofovir |
| NCT02367599 Effect of Vitamin D Supplementation on Bone Turnover Markers During PrEP in MSM | Patient Adherence | P4 | Completed | 48 | Open-label | Vitamin D Supplement |
| NCT00365612 Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients | HIV Infections | P4 | Completed | 300 | RCT, Open-label | Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF) |
| NCT01772940 Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting | HIV-1 Infection | P4 | Completed | 425 | RCT, Open-label | nevirapine, ritonavir-boosted Lopinavir, Tenofovir/emtricitabine, Zidovudine/lamivudine |
| NCT00840463 Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan | Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction | P4 | Terminated | 4 | RCT, Double-blind | Ambrisentan |
| NCT04530630 Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant | HIV Infections, Renal Transplant Rejection | P4 | Completed | 20 | Open-label | BIC/F/TAF 50Mg-200Mg-25Mg Tablet |
| NCT03350672 Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide | Hiv | P4 | Completed | 37 | Open-label | FTC/TAF |
| NCT01277601 Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B | Chronic Hepatitis B | P4 | Completed | 751 | RCT, Open-label | TDF, Peg-IFN |
| NCT02283060 Sleep and Cognition After Atripla to Stribild Switch | HIV | P4 | Unknown | 30 | RCT, Open-label | Stribild, Atripla |
| NCT00199121 A Pilot Study of Triple NtRTI/NsRTI Therapy in Antiretroviral Naive HIV-1 Infected Patients | HIV | P4 | Unknown | — | RCT, Open-label | Zidovudine (drug) |
| NCT01320943 Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB | Chronic Hepatitis B | P4 | Completed | 43 | RCT, Open-label | TDF |
| NCT02477527 Atripla to Stribild Switch Study to Evaluate Sleep Disturbances | HIV, AIDS | P4 | Completed | 21 | Open-label | Stribild |
| NCT03032666 Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial | Thalassemia, Hepatitis C | P4 | Completed | 7 | Open-label | sofosbuvir/velpatasvir |
| NCT02480166 Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6 | PT-NANBH | P4 | Completed | 60 | Open-label | 8 weeks SOF/LED, 12 weeks SOF/LED |
| NCT04538040 Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine | HIV-1-infection | P4 | Completed | 20 | Open-label | Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch |
| NCT04782180 PrEP at a Syringe Services Program | Hiv, Substance Use Disorders | P4 | Completed | 90 | Open-label | Descovy 200Mg 25Mg Tablet |
| NCT01711567 Tenofovir Disoproxil Fumarate vs. Entecavir in Chronic Hepatitis B Patients With Partial Virologic Response to Entecavir | Chronic Hepatitis B | P4 | Completed | 60 | RCT, Open-label | tenofovir, entecavir |
| NCT05159531 Virtual PrEP: Rendering PrEP Delivery More Efficient | HIV Infections | P4 | Terminated | 2 | RCT, Open-label | PrEP |
| NCT00323687 SONETT: Switch Study to Once Daily HIV Treatment Regimen With Truvada | HIV-1 Infection | P4 | Completed | 50 | Open-label | Truvada |
| NCT03842436 Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use | HIV/AIDS, Substance Use Disorders | P4 | Completed | 16 | Open-label | Truvada |
| NCT00670657 CRITIC - Treatment of Candidemia and Invasive Candidiasis | Candidemia, Invasive Candidiasis | P4 | Completed | 39 | Open-label | AmBisome |
| NCT01025427 HIV Persistence and Viral Reservoirs | HIV, HIV Infections | P4 | Completed | 16 | Open-label | Raltegravir, tenofovir/emtricitabine |
| NCT00389194 PREventing Progression of Adipose Tissue Redistribution | HIV Infections | P4 | Completed | 120 | RCT, Open-label | continuing AZT+3TC or switching AZT+3TC to TDF+ FTC |
| NCT02149888 PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5 | HIV, Human Immunodeficiency Virus | P4 | Completed | 52 | Open-label | Tenofovir/emtricitabine |
| NCT02858180 Hepatitis C Virus(HCV) Heart and Lung Study | Hepatitis C, Chronic, Heart Failure | P4 | Completed | 15 | Open-label | Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC) |
| NCT00648817 Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male Volunteers | HIV Infections | P4 | Completed | 8 | RCT, Double-blind | Tenofovir Disoproxil Fumarate, Tenofovir DF placebo |
| NCT01522625 Tenofovir in Chronic Hepatitis B With Mild ALT Elevation | Chronic Hepatitis B | P4 | Completed | 160 | RCT, Double-blind | tenofovir disoproxil fumarate 300mg per day, Placebo |
| NCT01051960 Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan | Systemic Sclerosis, Shortness of Breath | P4 | Completed | 12 | Open-label | Ambrisentan |
| NCT03998176 Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE | HIV-1-infection | P4 | Completed | 43 | Open-label | Bictegravir/emtricitabine/tenofovir alafenamide |
| NCT00127959 Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection | HIV Infections, Hepatitis B | P4 | Completed | 24 | RCT, Open-label | tenofovir, emtricitabine, zidovudine, efavirenz |
| NCT01488526 Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus | Hepatitis B Infection, Chronic Infection | P4 | Completed | 200 | RCT, Open-label | TDF treatment |
| NCT02829034 Targeting Right Ventricle in Pulmonary Hypertension Gilead | Pulmonary Hypertension | P4 | Completed | 22 | RCT, Double-blind | Ranolazine, Placebo |
| NCT00885664 Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection | HIV Infections | P4 | Completed | 60 | Open-label | Truvada (tenofovir/emtricitabine), Kaletra (lopinavir/ritonavir) |
| NCT04944654 Efficacy, Tolerability and Acceptability of Biktarvy by TPLWH | Human Immunodeficiency Virus | P4 | Terminated | 1 | Open-label | BIKTARVY 50Mg-200Mg-25Mg Tablet |
| NCT06104306 Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER) | HIV-1-infection | P4 | Completed | 33 | Open-label | B/F/TAF |
| NCT02308332 Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning | Neurocognitive Decline, HIV Associated Neurocognitive Disorder | P4 | Completed | 58 | RCT, Single-blind | Eviplera |
| NCT04843761 ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 | Covid19 | P3 | Completed | 473 | RCT, Double-blind | Remdesivir, Remdesivir Placebo, Aviptadil, Aviptadil Placebo, Corticosteroid |
| NCT00208312 ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI) | Coronary Artery Disease | P3 | Completed | 787 | RCT, Double-blind | Regadenoson, Adenosine |
| NCT06525389 Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST) | Talaromycosis | P3 | Not Yet Recruiting | 428 | RCT, Double-blind | Liposomal Amphotericin B (LAmB), Flucytosine (5FC), Flucytosine (5FC) placebo pill, Deoxycholate Amphotericin B (DAmB) |
| NCT02344290 Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults | HIV, Cardiovascular Diseases | P3 | Completed | 7,769 | RCT, Double-blind | Pitavastatin, Placebo |
| NCT00757237 Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa | Cystic Fibrosis | P3 | Completed | 274 | RCT, Open-label | Aztreonam for Inhalation Solution (AZLI), Tobramycin Inhalation Solution (TIS) |
| NCT00208299 ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI) | Coronary Artery Disease | P3 | Completed | 1,231 | RCT, Double-blind | Regadenoson, Adenosine |
| NCT02603107 Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults | HIV-1 Infection | P3 | Completed | 578 | RCT, Open-label | RTV, ATV, DRV, COBI, ATV/co, DRV/co, FTC/TDF, ABC/3TC, B/F/TAF |
| NCT02201901 Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis | Hepatitis C Virus Infection | P3 | Completed | 268 | RCT, Open-label | SOF/VEL, RBV |
| NCT01815736 Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants | HIV, HIV Infections | P3 | Completed | 1,443 | RCT, Open-label | E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF, RTV, ATV, FTC/TDF, COBI |
| NCT02487030 Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection | Hepatitis C Virus Infection | P3 | Completed | 255 | RCT, Open-label | LDV/SOF, RBV |
| NCT02074514 Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection | Chronic HCV Infection | P3 | Completed | 117 | RCT, Open-label | Sofosbuvir, RBV |
| NCT00712166 Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa | Cystic Fibrosis, Lung Infection | P3 | Completed | 160 | RCT, Double-blind | AZLI 75 mg three times daily (TID), Placebo three times daily (TID) |
| NCT04292899 Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | COVID-19 | P3 | Completed | 4,891 | RCT, Open-label | Remdesivir, Standard of Care |
| NCT05090410 Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate | Rheumatoid Arthritis, JAK Inhibitor | P3 | Unknown | 400 | RCT, Open-label | filgotinib 200mg/day, subcutaneous tocilizumab 162mg/biweekly |
| NCT00323544 SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection | HIV Infections | P3 | Completed | 220 | RCT, Open-label | zidovudine and lamivudine (Combivir®), emtricitabine and tenofovir DF |
| NCT04483687 Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy | Ankylosing Spondylitis | P3 | Withdrawn | — | RCT, Double-blind | Filgotinib, Placebo to Match Filgotinib |
| NCT02607930 Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults | HIV-1 Infection | P3 | Completed | 631 | RCT, Double-blind | ABC/DTG/3TC, B/F/TAF, ABC/DTG/3TC Placebo, B/F/TAF Placebo |
| NCT03053050 Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis | Nonalcoholic Steatohepatitis | P3 | Terminated | 808 | RCT, Double-blind | SEL, Placebo to match SEL 6 mg, Placebo to match SEL 18 mg |
| NCT02071082 Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults | HIV, HBV | P3 | Completed | 79 | Open-label | E/C/F/TAF |
| NCT01732913 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | Indolent Non-Hodgkin's Lymphomas | P3 | Terminated | 295 | RCT, Double-blind | Placebo, Rituximab, Idelalisib |
| NCT03219164 Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria | Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization, Cystic Fibrosis | P3 | Terminated | 149 | RCT, Double-blind | AZLI, Placebo |
| NCT01352416 Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery | Heart; Dysfunction Postoperative, Cardiac Surgery | P3 | Terminated | 15 | RCT, Double-blind | Ranolazine, Placebo |
| NCT02652624 Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women | HIV-1 Infection | P3 | Completed | 472 | RCT, Open-label | E/C/F/TAF, E/C/F/TDF, ATV, RTV, FTC/TDF, B/F/TAF |
| NCT01838590 Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection | Hepatitis C Virus | P3 | Completed | 103 | RCT, Open-label | SOF, RBV |
| NCT01872988 Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma | Chronic Hepatitis B, Hepatocellular Carcinoma | P3 | Terminated | 320 | RCT, Double-blind | Tenofovir, Placebo |
| NCT02607800 Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy | Hepatitis C | P3 | Completed | 943 | RCT, Open-label | SOF/VEL/VOX, SOF/VEL |
| NCT02300558 Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3 | Long QT Syndrome Type 3 | P3 | Terminated | 41 | Single-blind | Eleclazine, Eleclazine placebo |
| NCT02545504 Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric Adenocarcinoma | P3 | Completed | 432 | RCT, Double-blind | Andecaliximab, Placebo, Leucovorin, 5-fluorouracil, Oxaliplatin |
| NCT01349491 Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion | Atrial Fibrillation | P3 | Terminated | 10 | RCT, Double-blind | Ranolazine, Matching placebo |
| NCT01641640 Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection | Chronic Hepatitis C | P3 | Completed | 328 | Open-label | Sofosbuvir, RBV, PEG |
| NCT06613685 Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated | HIV-1-infection | P2P3 | Terminated | 73 | RCT, Double-blind | GS-1720, GS-4182, Bictegravir/emtricitabine/tenofovir alafenamide, GS-1720/GS-4182 FDC, Placebo to Match BVY, Placebo to Match GS1720/GS-4182 FDC |
| NCT02073656 Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection | Hepatitis C Virus, HIV | P3 | Completed | 335 | Open-label | LDV/SOF, RBV |
| NCT02616029 Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I | HIV-1 Infection | P3 | Completed | 66 | RCT, Open-label | E/C/F/TAF |
| NCT00389779 DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension | Hypertension | P3 | Completed | 849 | RCT, Double-blind | Darusentan, Guanfacine, Darusentan Placebo |
| NCT02346721 Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection | Hepatitis C Virus Infection | P3 | Completed | 111 | Open-label | SOF/VEL |
| NCT00777920 Study of Ambrisentan in Participants With Pulmonary Hypertension | Pulmonary Hypertension | P3 | Completed | 140 | Open-label | Ambrisentan |
| NCT02914600 Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease | Crohn's Disease | P3 | Terminated | 1,188 | Double-blind | Filgotinib, Placebo |
| NCT01896193 Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection | Hepatitis C | P3 | Completed | 127 | RCT, Open-label | SOF, RBV |
| NCT02201953 Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection | Hepatitis C Virus Infection | P3 | Completed | 558 | RCT, Open-label | SOF/VEL, SOF, RBV |
| NCT02886728 Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy | Rheumatoid Arthritis | P3 | Completed | 1,252 | RCT, Double-blind | Filgotinib, Placebo to match filgotinib, MTX, Placebo to match MTX |
| NCT01962441 SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection | Hepatitis C | P3 | Completed | 601 | RCT, Open-label | SOF, RBV, Peg-IFN |
| NCT03118843 Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study | Hepatitis C Virus Infection | P3 | Completed | 31 | Open-label | SOF/VEL/VOX |
| NCT02639247 Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor | Hepatitis C Virus Infection | P3 | Completed | 333 | RCT, Open-label | SOF/VEL/VOX, SOF/VEL |
| NCT03547908 Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults | HIV-1/HBV Co-Infection | P3 | Completed | 244 | RCT, Double-blind | B/F/TAF, Placebo to match DTG, Placebo to match F/TDF, DTG, F/TDF, Placebo to match B/F/TAF |
| NCT02613871 Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection | Hepatitis C Virus Infection | P3 | Completed | 111 | Open-label | LDV/SOF |
| NCT02738333 Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection | Hepatitis C Virus Infection | P3 | Completed | 239 | RCT, Open-label | LDV/SOF, SOF, RBV |
| NCT00528957 Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children | HIV Infections | P3 | Completed | 97 | RCT, Open-label | Tenofovir DF, Zidovudine, Stavudine |
| NCT01495702 Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients | Acquired Immunodeficiency Syndrome, HIV Infections | P3 | Completed | 439 | RCT, Open-label | NNRTI, FTC/TDF, Stribild |
| NCT01701401 Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV | Chronic Hepatitis C Virus | P3 | Completed | 870 | RCT, Open-label | LDV/SOF, RBV |
| NCT02707601 Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment | HIV-1 Infection, HCV Infection | P3 | Completed | 150 | RCT, Open-label | E/C/F/TAF, F/R/TAF, LDV/SOF |
| NCT02603120 Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed | HIV-1 Infection | P3 | Completed | 567 | RCT, Double-blind | ABC/DTG/3TC, B/F/TAF, ABC/DTG/3TC Placebo, B/F/TAF Placebo |
| NCT01569295 Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) | Chronic Lymphocytic Leukemia | P3 | Completed | 416 | RCT, Double-blind | Idelalisib, Rituximab, Bendamustine, Placebo to match idelalisib |
| NCT03110380 Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed | HIV-1-infection | P3 | Completed | 567 | RCT, Double-blind | B/F/TAF, F/TAF, DTG, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo |
| NCT00302822 Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130) | HIV Infections, AIDS | P3 | Completed | 195 | RCT, Open-label | enfuvirtide, emtricitabine/tenofovir, lopinavir or efavirenz |
| NCT04742491 Pre-Exposure Prophylaxis for Transgender Women in the US and South America | HIV Prevention | P2P3 | Completed | 304 | RCT, Open-label | Immediate Intervention Arm, Deferred Intervention Arm |
| NCT01967940 Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults | HIV, HIV Infections | P3 | Completed | 55 | RCT, Double-blind | TAF, Placebo, E/C/F/TAF, Current failing ARV regimen, ATV |
| NCT01641822 Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF | Cystic Fibrosis | P3 | Completed | 107 | RCT, Double-blind | AZLI, Placebo to match AZLI, Tobramycin inhalation solution |
| NCT03631732 Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants | HIV-1 Infection | P3 | Completed | 496 | RCT, Open-label | B/F/TAF, NRTIs, Third Agent |
| NCT00330369 DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension | Hypertension | P3 | Completed | 352 | RCT, Double-blind | Darusentan, Darusentan Placebo |
| NCT01259713 Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic Leukemia | Invasive Fungal Disease | P3 | Completed | 355 | RCT, Double-blind | Liposomal amphotericin B, Placebo |
| NCT00263315 Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis | Aspergillosis | P2P3 | Completed | 320 | RCT, Double-blind | nebulised liposomal amphotericin B |
| NCT00737568 Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine | Hepatitis B | P3 | Completed | 280 | RCT, Double-blind | TDF, FTC/TDF, TDF Placebo, FTC/TDF Placebo |
| NCT02520284 Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | P2P3 | Terminated | 165 | RCT, Double-blind | Andecaliximab, Placebo |
| NCT01539291 Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512) | Chronic Lymphocytic Leukemia | P3 | Terminated | 161 | RCT, Double-blind | Idelalisib |
| NCT00099788 Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes | Myocardial Ischemia | P3 | Completed | 6,560 | RCT, Double-blind | Ranolazine, Placebo |
| NCT02639338 Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis | Hepatitis C Virus Infection | P3 | Completed | 220 | RCT, Open-label | SOF/VEL/VOX, SOF/VEL |
| NCT00112359 International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa | Cystic Fibrosis | P3 | Completed | 166 | RCT, Double-blind | AZLI 75 mg three times a day (TID), Placebo three times a day (TID) |
| NCT02345226 Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults | HIV-1 Infection | P3 | Completed | 881 | RCT, Double-blind | FTC/RPV/TAF, EFV/FTC/TDF Placebo, EFV/FTC/TDF, FTC/RPV/TAF Placebo |
| NCT04527991 Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread | Locally Advanced or Metastatic Unresectable Urothelial Cancer | P3 | Completed | 712 | RCT, Open-label | Sacituzumab Govitecan-hziy, Paclitaxel, Docetaxel, Vinflunine |
| NCT01705574 Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women | Acquired Immunodeficiency Syndrome, HIV Infections | P3 | Completed | 583 | RCT, Double-blind | E/C/F/TDF, ATV, RTV, FTC/TDF, E/C/F/TDF Placebo, ATV Placebo, RTV Placebo, FTC/TDF Placebo, E/C/F/TAF |
| NCT02836236 Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China) | HBV, Chronic HBV Infection | P3 | Completed | 155 | RCT, Double-blind | TAF, TDF, TAF Placebo, TDF Placebo |
| NCT01923311 Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants | Acquired Immune Deficiency Syndrome (AIDS), HIV Infections | P2P3 | Terminated | 31 | Open-label | EVG, Background regimen |
| NCT00936195 Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial | HIV Infection, Pregnancy | P3 | Withdrawn | — | RCT, Open-label | Efavirenz-Tenofovir-Emtricitabine, Zidovudine-Lamivudine-Lopinavir/Ritonavir |
| NCT00768300 (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF | Idiopathic Pulmonary Fibrosis | P3 | Terminated | 494 | RCT, Double-blind | Ambrisentan, Placebo |
| NCT01309243 Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | HIV-1 Infection | P3 | Completed | 799 | RCT, Open-label | FTC/RPV/TDF, EFV/FTC/TDF |
| NCT01980888 Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | P3 | Terminated | 311 | RCT, Double-blind | Idelalisib, Bendamustine, Rituximab, Placebo |
| NCT00578786 A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202) | Pulmonary Arterial Hypertension | P3 | Completed | 383 | RCT, Double-blind | ambrisentan |
| NCT03696160 The Late Presenter Treatment Optimisation Study | HIV/AIDS | P3 | Completed | 447 | RCT, Open-label | Biktarvy, Symtuza |
| NCT00128492 Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA) | Cystic Fibrosis | P3 | Completed | 274 | Open-label | AZLI 75 mg two times a day (BID)/ three times a day (TID) |
| NCT01404234 Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways | Cystic Fibrosis, Pseudomonas Aeruginosa | P3 | Completed | 61 | Open-label | AZLI |
| NCT00391638 Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients | Hepatitis B, HIV Infections | P2P3 | Completed | 56 | Open-label | TRUVADA (EMTRICITABINE + TENOFOVIR DF), PEGASYS 180μg (Interféron pégylé alpha -2a) |
| NCT01780506 Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults | HIV, HIV Infections | P3 | Completed | 872 | RCT, Double-blind | E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo |
| NCT03890120 Study of Cilofexor in Adults With Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | P3 | Terminated | 419 | RCT, Double-blind | Cilofexor, Placebo |
| NCT01494987 Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | P3 | Completed | 431 | RCT, Double-blind | Ranolazine, Placebo, Glimepiride |
| NCT05603143 Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness | COVID-19 | P3 | Terminated | 468 | RCT, Double-blind | Obeldesivir, Obeldesivir Placebo |
| NCT02998320 Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis | HIV Risk | P3 | Completed | 101 | Open-label | Genvoya |
| NCT01783678 A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults | Chronic Hepatitis C, Human Immunodeficiency Virus | P3 | Completed | 275 | RCT, Open-label | Sofosbuvir, RBV |
| NCT02914522 Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | P3 | Completed | 1,351 | RCT, Double-blind | Filgotinib, PTM filgotinib |
| NCT00112047 Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects | HIV Infections | P3 | Completed | 517 | RCT, Open-label | Emtricitabine (FTC), Tenofovir Disoproxil Fumarate (TDF), Efavirenz (EFV), FTC/TDF, FTC/TDF/EFV, Lamivudine/zidovudine |
| NCT01442038 Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI) | Coronary Artery Disease, Angina Pectoris | P3 | Completed | 2,651 | RCT, Double-blind | Ranolazine, Placebo |
| NCT04501952 Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting | COVID-19 | P3 | Terminated | 584 | RCT, Double-blind | RDV, Placebo to Match RDV |
| NCT02914561 Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease | Crohn's Disease | P3 | Completed | 1,372 | RCT, Double-blind | Filgotinib |
| NCT00003338 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma | Lymphoma | P2P3 | Unknown | 60 | — | — |
| NCT03602560 ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) | Primary Biliary Cholangitis | P3 | Completed | 265 | RCT, Double-blind | seladelpar 5-10 mg, seladelpar 10 mg, Placebo |
| NCT02607956 Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults | HIV-1 Infection | P3 | Completed | 657 | RCT, Double-blind | DTG, F/TAF, B/F/TAF, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo |
| NCT01980875 Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | P3 | Terminated | 57 | RCT, Open-label | Idelalisib, Chlorambucil, Obinutuzumab |
| NCT01440569 Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults | Acquired Immunodeficiency Syndrome, HIV Infections | P3 | Completed | 314 | Open-label | COBI, DRV, NRTIs |
| NCT01472185 Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus | Type 2 Diabetes Mellitus | P3 | Completed | 465 | RCT, Double-blind | Ranolazine, Placebo |
| NCT03074786 Reversing the Epidemic in Africa With Choices in HIV Prevention (REACH) | HIV-1-infection | P2 | Withdrawn | — | RCT, Open-label | Dapivirine, Truvada |
| NCT04262856 Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer | Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer | P2 | Completed | 151 | RCT, Open-label | Domvanalimab, Etrumadenant, Zimberelimab |
| NCT03434353 Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB) | Chronic Hepatitis B | P2 | Terminated | 123 | RCT, Open-label | Inarigivir Soproxil, TAF |
| NCT00419770 The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study | Mucormycosis | P2 | Completed | 20 | RCT, Double-blind | deferasirox, Placebo, Liposomal amphotericin B |
| NCT01067443 Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa | Primary Visceral Leishmaniasis | P2 | Completed | 151 | RCT, Open-label | Liposomal amphotericin B (AmBisome®) and sodium stibogluconate, Liposomal amphotericin B + miltefosine, Miltefosine |
| NCT04891770 Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) | Chronic Hepatitis B | P2 | Completed | 103 | RCT, Open-label | Tenofovir Alafenamide, VIR-2218, Nivolumab, Selgantolimod |
| NCT01435044 Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection | Hepatitis C, Chronic | P2 | Completed | 239 | RCT, Double-blind | Sofosbuvir, GS-0938, RBV, Placebo to match sofosbuvir, Placebo to match GS-0938 |
| NCT03869190 Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) | Urothelial Carcinoma, Bladder Cancer | P1P2 | Completed | 272 | RCT, Open-label | Atezolizumab, Enfortumab Vedotin, Niraparib, Magrolimab (Hu5F9-G4), Tiragolumab, Sacituzumab Govitecan, Tocilizumab, Cisplatin, Gemcitabine |
| NCT02926833 Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Refractory Diffuse Large B Cell Lymphoma | P1P2 | Completed | 37 | Open-label | KTE-C19, Atezolizumab, Cyclophosphamide, Fludarabine |
| NCT04660812 An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. | Metastatic Colorectal Cancer | P1P2 | Completed | 227 | RCT, Single-blind | AB680, Etrumadenant, Zimberelimab, Bevacizumab, m-FOLFOX-6 regimen, Regorafenib |
| NCT04381832 Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer | Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms | P1P2 | Completed | 173 | RCT, Open-label | Etrumadenant, Zimberelimab, Quemliclustat, Enzalutamide, Docetaxel, SG |
| NCT01887353 The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure | Atrial Fibrillation, Heart Failure | P2 | Terminated | 8 | RCT, Double-blind | Ranolazine, Placebo |
| NCT01055847 Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection | Cystic Fibrosis, CF | P2 | Completed | 105 | RCT, Double-blind | Aztreonam for Inhalation (AI), Placebo |
| NCT02745535 Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience | Chronic Hepatitis C | P2 | Completed | 77 | Open-label | Sofosbuvir/Velpatasvir/Voxilaprevir |
| NCT01225380 A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C | Chronic Hepatitis C Infection | P2 | Completed | 324 | RCT, Double-blind | GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo, Pegasys®, Copegus® |
| NCT00713401 Safety Study of Tecadenoson to Treat Atrial Fibrillation | Atrial Fibrillation | P2 | Completed | 21 | Open-label | Tecadenoson, Esmolol |
| NCT02955602 Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC) | Primary Biliary Cirrhosis | P2 | Completed | 119 | RCT, Open-label | MBX-8025 2 mg Capsule, MBX-8025 5 mg Capsule, MBX-8025 10 mg Capsule |
| NCT01329978 Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6 | Hepatitis C, Chronic | P2 | Completed | 332 | RCT, Open-label | Sofosbuvir, RBV, PEG |
| NCT01965535 Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection | HCV Infection | P2 | Completed | 155 | RCT, Double-blind | LDV/SOF, RBV, Placebo to match LDV/SOF, Placebo to match RBV |
| NCT00120367 Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125) | Leukoencephalopathy, Progressive Multifocal, HIV Infections | P2 | Completed | 30 | Open-label | Enfuvirtide, Tenofovir-Emtricitabine |
| NCT00701883 Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol | Hyperlipidemia | P2 | Completed | 183 | RCT, Double-blind | Placebo, MBX-8025, MBX-8025, Atorvastatin, MBX-8025, MBX-8025 |
| NCT03551522 A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH) | NASH - Nonalcoholic Steatohepatitis | P2 | Terminated | 181 | RCT, Double-blind | Seladelpar, Placebos |
| NCT01072695 Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection | HCV Infection | P2 | Completed | 46 | RCT, Open-label | GS-9256, GS-9190, Ribavirin, Peginterferon alfa-2a |
| NCT03992131 A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | Ovarian Cancer, Triple-negative Breast Cancer | P1P2 | Terminated | 25 | Open-label | Rucaparib, Lucitanib, Sacituzumab govitecan |
| NCT01648205 Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients | Long QT Syndrome | P2 | Completed | 25 | Double-blind | Placebo, Ranolazine |
| NCT00597129 Safety and Efficacy Study of 90Y-hPAM4 at Different Doses | Pancreatic Cancer | P1P2 | Completed | 21 | Open-label | 90Y-hPAM4 |
| NCT00603668 Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL | Chronic Lymphocytic Lymphoma | P1P2 | Completed | 19 | Open-label | milatuzumab |
| NCT01672853 Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC) | Primary Sclerosing Cholangitis (PSC) | P2 | Completed | 235 | RCT, Double-blind | Simtuzumab, Placebo |
| NCT05629208 Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE) | Cutaneous Lupus Erythematosus (CLE) | P2 | Terminated | 20 | RCT, Double-blind | Edecesertib, Edecesertib Placebo |
| NCT02309918 HepNet Acute HCV IV - LDV/SOF FDC in Acute Genotype 1 Hepatitis C Virus Infection | Acute Hepatitis C | P2 | Completed | 20 | Open-label | LDV/SOF FDC |
| NCT02590588 Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis | Amyloidosis | P2 | Terminated | 1 | Open-label | Idelalisib |
| NCT00196599 Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults | HIV Infections, Antiretroviral Naive | P2 | Completed | 39 | Open-label | emtricitabine, FTC (drug), didanosine, ddI (drug), efavirenz (drug) |
| NCT00507689 Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant | Chronic Hepatitis B | P2 | Completed | 40 | RCT, Double-blind | FTC/TDF, Hepatitis B Immunoglobulin (HBIg) |
| NCT00743340 Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to Emtricitabine | HIV-1 Infection | P2 | Completed | 50 | Open-label | Emtricitabine |
| NCT02968563 Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | Chronic Lymphocytic Leukemia | P2 | Completed | 35 | Open-label | Tirabrutinib, Idelalisib, Obinutuzumab |
| NCT01943799 Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B | Chronic HBV Infection | P2 | Completed | 178 | RCT, Open-label | GS-4774, OAV Regimen |
| NCT05165771 Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment | Rheumatoid Arthritis | P2 | Withdrawn | — | RCT, Double-blind | GS-5718, GS-5718, Placebo to match GS-5718, Tofacitinib 5 mg, Placebo to match Tofacitinib |
| NCT02472535 Study to Evaluate the Effects of MBX-8025 in Patients With HoFH | Homozygous Familial Hypercholesterolemia | P2 | Completed | 13 | Open-label | MBX-8025 50 mg (Dose Escalation Period 1), MBX-8025 50 mg or 100 mg (Dose Escalation Period 2), MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3) |
| NCT02943460 Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis | Primary Sclerosing Cholangitis | P2 | Completed | 52 | RCT, Double-blind | Cilofexor, Placebo to match cilofexor |
| NCT02219685 Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection | Hepatitis C Virus Infection | P2 | Completed | 40 | RCT, Double-blind | LDV/SOF, Placebo |
| NCT02226549 Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis | Hepatitis C Virus Infection | P2 | Completed | 47 | RCT, Open-label | LDV/SOF, VDV, RBV |
| NCT02378961 Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection | Hepatitis C Virus Infection | P2 | Completed | 128 | Open-label | VOX, SOF/VEL |
| NCT01938430 Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant | Chronic HCV Infection | P2 | Completed | 339 | RCT, Open-label | LDV/SOF, RBV |
| NCT01416402 Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients | Hyperuricemia, Gout | P2 | Completed | 27 | Open-label | Arhalofenate, Febuxostat, Colchicine |
| NCT03100942 Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome | Sjogren's Syndrome | P2 | Completed | 152 | RCT, Double-blind | Lanraplenib, Filgotinib, Tirabrutinib, Lanraplenib placebo, Filgotinib placebo, Tirabrutinib placebo |
| NCT03046056 Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD) | Small Bowel Crohn's Disease | P2 | Completed | 78 | RCT, Double-blind | Filgotinib, Placebo to match filgotinib |
| NCT03036852 Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease | Chronic Hepatitis C | P2 | Completed | 59 | Open-label | SOF/VEL |
| NCT00596804 Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma, Lymphoma, Diffuse | P1P2 | Completed | 39 | Open-label | veltuzumab |
| NCT00041652 Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer | Colorectal Cancer, Colon Cancer | P1P2 | Completed | 30 | Open-label | hMN14 (labetuzumab) |
| NCT02445131 Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG) | Chronic Lymphocytic Leucemia | P2 | Completed | 48 | Open-label | Bendamustine, GA101, CAL-101 |
| NCT01707472 Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis | Liver Fibrosis, Hepatitis C | P2 | Completed | 18 | Open-label | Simtuzumab |
| NCT02300103 Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study | Hepatitis C Virus Infection | P2 | Completed | 69 | Open-label | SOF/VEL, RBV |
| NCT00061425 Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG | Non-Hodgkin's Lymphoma, Lymphoma, B-Cell | P1P2 | Completed | — | Open-label | radiolabeled epratuzumab |
| NCT02607228 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer | Metastatic Castrate-Resistant Prostate Cancer | P1P2 | Terminated | 31 | Open-label | Alobresib, Enzalutamide |
| NCT00892437 Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | HIV-1 Infection | P2 | Completed | 85 | RCT, Double-blind | COBI, RTV, ATV, FTC/TDF, COBI placebo, RTV placebo |
| NCT00326157 PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem Cell Transplantation | Fungus Diseases | P2 | Completed | 34 | Open-label | AmBisome |
| NCT01203930 A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | P2 | Terminated | 105 | Open-label | Idelalisib, Rituximab |
| NCT02994056 Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis | Hepatitis C Virus Infection | P2 | Completed | 32 | Open-label | SOF/VEL, RBV |
| NCT02781571 Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant | Hepatitis C Virus Infection | P2 | Completed | 79 | Open-label | SOF/VEL |
| NCT00869557 Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults | HIV, HIV Infections | P2 | Completed | 71 | RCT, Double-blind | Stribild, Atripla |
| NCT01163734 Ranolazine in Diastolic Heart Failure | Diastolic Heart Failure | P2 | Completed | 20 | RCT, Double-blind | Ranolazine |
| NCT01808248 Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3 | Hepatitis C | P2 | Completed | 47 | Open-label | SOF, PEG, RBV |
| NCT00989586 Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Lymphoma | P1P2 | Completed | 35 | Open-label | milatuzumab, veltuzumab, veltuzumab and milatuzumab |
| NCT02568683 Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) | Non-Hodgkin Lymphoma | P1P2 | Terminated | 10 | Open-label | Entospletinib, Vincristine |
| NCT00547066 Study of Veltuzumab (hA20) at Different Doses in Patients With ITP | Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopenic Purpura | P1P2 | Terminated | 48 | Open-label | veltuzumab |
| NCT02614066 A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) | Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | P1P2 | Completed | 125 | Open-label | brexucabtagene autoleucel, Cyclophosphamide, Fludarabine |
| NCT00664378 Efficacy Study of CYT997 in Multiple Myeloma | Relapsed and Refractory Multiple Myeloma | P2 | Terminated | 5 | Open-label | CYT997 |
| NCT00298350 Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART. | HIV, HIV-1 | P2 | Completed | 278 | RCT, Double-blind | GS-9137 - A Novel HIV-1 Integrase Inhibitor |
| NCT03118674 Harvoni Treatment Porphyria Cutanea Tarda | Porphyria Cutanea Tarda, Hepatitis C | P2 | Completed | 23 | Open-label | Harvoni |
| NCT01631552 Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | Gastric Adenocarcinoma, Esophageal Cancer | P1P2 | Completed | 515 | Open-label | Sacituzumab Govitecan-hziy (SG) |
| NCT02983604 GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer | Advanced Estrogen Receptor Positive HER2- Breast Cancer | P1P2 | Terminated | 14 | Open-label | GS-5829, Exemestane, Fulvestrant |
| NCT02728206 Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation | Hepatitis C Virus Infection | P2 | Completed | 9 | Open-label | SOF/VEL |
| NCT04130919 Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | P2 | Terminated | 19 | RCT, Double-blind | Tilpisertib, Placebo |
| NCT00451711 Intermittent Liposomal Amphotericin B Primary Prophylaxis | Acute Myeloid Leukemia | P2 | Unknown | 60 | RCT, Open-label | Liposomal amphotericin B |
| NCT01915472 A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | P2 | Withdrawn | — | RCT, Open-label | IMMU 130 |
| NCT04066881 A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP | HIV Infections | P2 | Completed | 1,512 | RCT, Double-blind | Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48), Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48), Vaccine Group C: Saline placebo (weeks 0,4,24,48), Control PrEP:TDF/FTC once daily (weeks 0-26), Experimental PrEP:TAF/FTC once daily (weeks 0-26) |
| NCT00740610 Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH) | Nonalcoholic Steatohepatitis | P2 | Completed | 124 | RCT, Double-blind | GS-9450, GS-9450 Placebo |
| NCT01687257 Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation | Hepatitis C, Cirrhosis | P2 | Completed | 50 | RCT, Open-label | SOF, RBV |
| NCT01479465 Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma | Colorectal Cancer | P2 | Terminated | 266 | RCT, Double-blind | Simtuzumab, Placebo to match SIM, Leucovorin, Irinotecan, Fluorouracil |
| NCT01924949 Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection | Hepatitis C | P2 | Completed | 5 | Open-label | LDV/SOF |
| NCT01435226 GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection | Hepatitis C, Chronic | P2 | Completed | 170 | RCT, Double-blind | GS-5885, GS-9451, tegobuvir, placebo to match tegobuvir, placebo to match RBV, Ribavirin |
| NCT01984294 Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection | Chronic HCV Infection | P2 | Completed | 101 | RCT, Open-label | LDV/SOF, RBV, GS-9669 |
| NCT01605890 Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients | HIV-2 Infection | P2 | Completed | 30 | Open-label | emtricitabine / tenofovir disoproxil fumarate / raltegravir . |
| NCT02378935 Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection | Hepatitis C Virus Infection | P2 | Completed | 205 | Open-label | VOX, SOF/VEL, RBV |
| NCT03285711 Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN) | Lupus Membranous Nephropathy | P2 | Completed | 9 | RCT, Double-blind | Filgotinib, Lanraplenib, Filgotinib placebo, Lanraplenib placebo |
| NCT01730612 ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA | HER2 Negative Breast Carcinoma Expressing CEA | P1P2 | Completed | 23 | Open-label | TF2 - 68 Ga-IMP-288: |
| NCT01528865 Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma | Lymphoma | P1P2 | Withdrawn | — | Open-label | Lamivudine, Tenofovir disoproxil fumarate |
| NCT02405442 Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease | Crohn's Disease | P2 | Terminated | 187 | RCT, Double-blind | Andecaliximab, Placebo |
| NCT02457611 Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection | Hepatitis C Infection With HIV Co-Infection | P2 | Completed | 26 | Open-label | LDV/SOF |
| NCT01713283 Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection | Hepatitis C Virus | P2 | Completed | 60 | RCT, Open-label | SOF, RBV |
| NCT01271790 A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C | Hepatitis C, Chronic | P2 | Completed | 245 | RCT, Double-blind | Tegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, GS-9451, Tegobuvir placebo, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo, Pegasys®, Copegus® |
| NCT00307489 Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil | Chronic Hepatitis B | P2 | Completed | 106 | RCT, Double-blind | tenofovir DF, emtricitabine /tenofovir DF |
| NCT01282424 Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas | Follicular Lymphoma, Small Lymphocytic Lymphoma | P2 | Completed | 125 | Open-label | Idelalisib |
| NCT02466516 Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3 | Non-Alcoholic Steatohepatitis (NASH) | P2 | Completed | 72 | RCT, Open-label | SEL, SIM |
| NCT01371578 Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection | Hepatitis C, Chronic | P2 | Completed | 163 | Open-label | GS-5885 tablet, GS-9451 tablet, peginterferon alfa-2a, ribavirin tablet |
| NCT00002415 Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination to Treat HIV-Infected Patients | HIV Infections | P2 | Completed | 175 | Double-blind | Tenofovir disoproxil fumarate |
| NCT04880577 Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting, Fatigue | P2 | Withdrawn | — | RCT, Double-blind | TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY], Placebo |
| NCT06046482 Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma | Head Neck, Squamous Cell Carcinoma of Head and Neck | P2 | Terminated | 4 | RCT, Open-label | Pembrolizumab, Magrolimab, cetuximab, Docetaxel |
| NCT02251717 Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection | Hepatitis C Virus Infection | P2 | Completed | 114 | RCT, Open-label | LDV/SOF |
| NCT00364026 A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Blood Pressure Lowering Drugs | Hypertension | P2 | Completed | — | RCT, Double-blind | darusentan |
| NCT00907764 Stress Echocardiography Study With Regadenoson | Heart Disease, Coronary Artery Disease | P2 | Terminated | 22 | Open-label | regadenoson |
| NCT02254408 Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract | Respiratory Syncytial Virus | P2 | Completed | 189 | RCT, Double-blind | Presatovir, Placebo |
| NCT02147067 Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA) | Microvascular Angina | P2 | Completed | 26 | RCT, Double-blind | Ranolazine, Placebo |
| NCT00645294 Open Label Study of Pharmacokinetics and Safety of Dose of Adefovir Dipivoxil in Children and Adolescents With HBV | Hepatitis B | P1P2 | Completed | 47 | RCT, Open-label | Adefovir dipivoxil, Adefovir Dipivoxil, Adefovir Dipivoxil |
| NCT02397694 Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults | HIV-1 Infection | P2 | Completed | 98 | RCT, Double-blind | BIC, F/TAF, DTG, BIC Placebo, DTG Placebo, B/F/TAF |
| NCT00476463 Efficacy of Tenofovir and Emtricitabine in ARV-naive Patients With HIV/HBV Co-infection | Hepatitis B Virus, HIV Infections | P2 | Completed | 24 | RCT, Open-label | Emtricitabine |
| NCT02701634 Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD) | Chronic Graft Versus Host Disease | P2 | Terminated | 66 | RCT, Double-blind | ENTO, Placebo |
| NCT02063997 Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients | Gout | P2 | Completed | 248 | RCT, Double-blind | Arhalofenate 600 mg, Allopurinol 300 mg, Colchicine 0.6 mg, Placebo, Arhalofenate 800 mg |
| NCT02818582 GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen | Ebola | P2 | Completed | 38 | RCT, Double-blind | GS-5734 |
| NCT05537766 Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies | Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation | P2 | Terminated | 19 | Open-label | Brexucabtagene Autoleucel, Cyclophosphamide, Fludarabine |
| NCT03449446 Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Steatohepatitis | P2 | Completed | 395 | RCT, Double-blind | SEL, FIR, CILO, Placebo to match FIR, Placebo to match CILO, Placebo to match SEL |
| NCT04539262 Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation | COVID-19 | P1P2 | Completed | 156 | RCT, Double-blind | Remdesivir (RDV), Placebo |
| NCT00424021 Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension | Pulmonary Hypertension | P2 | Completed | 54 | Open-label | ambrisentan |
| NCT02377336 GS-6615 in Adults With Chronic Stable Angina and Coronary Artery Disease | Ischemic Heart Disease | P2 | Withdrawn | — | RCT, Double-blind | GS-6615, Placebo |
| NCT01353248 GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection | Hepatitis C, Chronic | P2 | Completed | 141 | RCT, Open-label | GS-5885, Tegobuvir, GS-9451, ribavirin tablet, GS-5885 |
| NCT01356160 GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus | Hepatitis C, Chronic | P2 | Completed | 351 | RCT, Double-blind | GS-5885, GS-9451, peginterferon alfa-2a, ribavirin tablet, GS-9451 Placebo |
| NCT01909804 Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection | Hepatitis C | P2 | Completed | 323 | RCT, Open-label | SOF, VEL, RBV |
| NCT02166047 Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants | Chronic Hepatitis B | P2 | Completed | 162 | RCT, Double-blind | Vesatolimod, Placebo |
| NCT02265796 Ranolazine Among Unrevascularized Chronic Stable Angina Patients | Angina | P2 | Completed | 50 | RCT, Double-blind | Ranolazine, Sugar pill |
| NCT03386578 Evaluating the Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for HIV Prevention During Pregnancy and Postpartum | HIV Infections | P2 | Completed | 780 | Open-label | Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) |
| NCT00040599 Safety Study of 90Y-hMN14 to Treat Colorectal Cancer | Colorectal Cancer, Colon Cancer | P1P2 | Completed | 72 | Open-label | hMN14 (labetuzumab) |
| NCT05459571 Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma | Relapsed or Refractory Large B-cell Lymphoma | P2 | Completed | 35 | Open-label | Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Dexamethasone |
| NCT02254421 Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract | Respiratory Syncytial Virus Infection | P2 | Completed | 60 | RCT, Double-blind | Presatovir, Placebo |
| NCT03133221 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation | Non Hodgkin Lymphoma, Follicular Lymphoma | P2 | Completed | 17 | Open-label | Zydelig |
| NCT00832507 Study of Cicletanine for Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension | P2 | Terminated | 162 | RCT, Double-blind | Cicletanine, Cicletanine Placebo |
| NCT01672879 Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH | Liver Fibrosis Due to NASH | P2 | Terminated | 259 | RCT, Double-blind | Placebo, SIM |
| NCT06784973 Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection | RSV Infection | P2 | Terminated | 4 | RCT, Double-blind | Obeldesivir, Obeldesivir Placebo |
| NCT02348216 Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma | Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma | P1P2 | Completed | 307 | Open-label | Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone |
| NCT07474558 SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates | Advanced or Metastatic Solid Tumour, Antibody-Drug Conjugate | P2 | Not Yet Recruiting | 102 | RCT, Open-label | Antibody-Drug Conjugates |
| NCT01565850 D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults | Acquired Immunodeficiency Syndrome, HIV Infections | P2 | Completed | 153 | RCT, Double-blind | D/C/F/TAF, DRV, COBI, FTC/TDF, D/C/F/TAF Placebo, DRV Placebo, COBI Placebo, FTC/TDF Placebo |
| NCT01101581 Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL | Non Hodgkin's Lymphoma, NHL | P1P2 | Withdrawn | — | RCT, Open-label | Veltuzumab and 90Y-Epratuzumab Tetraxetan, 90Y-epratuzumab tetraxetan, veltuzumab |
| NCT02953782 Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer | Solid Tumor, Colorectal Cancer | P1P2 | Completed | 78 | Open-label | Magrolimab, Cetuximab |
| NCT03852433 Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD) | Chronic Hepatitis Delta | P2 | Completed | 175 | RCT, Open-label | Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa) |
| NCT03472326 Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus | HIV-1-infection | P2 | Terminated | 21 | RCT, Double-blind | GS-9131, BIC, TAF, ARV regimen, DRV, RTV |
| NCT04772989 A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies | Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC) | P1 | Completed | 94 | Open-label | AB308, Zimberelimab |
| NCT00561496 Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel | HIV Infections | P1 | Completed | 49 | Open-label | Tenofovir gel |
| NCT04314843 Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma | Relapsed/Refractory Large B-cell Lymphoma | P1 | Terminated | 6 | Open-label | Cyclophosphamide, Fludarabine, Lenzilumab, Axicabtagene Ciloleucel |
| NCT03846310 A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer | Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer | P1 | Completed | 77 | Open-label | Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab |
| NCT05277012 A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants | Healthy Participants | P1 | Completed | 24 | RCT, Open-label | Etrumadenant |
| NCT04087018 Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Completed | 18 | Open-label | zimberelimab |
| NCT03628677 A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | Solid Tumor, Unspecified, Adult | P1 | Completed | 75 | Open-label | Domvanalimab, Zimberelimab |
| NCT05411146 A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer | Healthy Participants | P1 | Completed | 8 | Open-label | [14C]-etrumadenant |
| NCT01838434 Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | Relapsed/Refractory Mantle Cell Lymphoma | P1 | Completed | 106 | RCT, Open-label | lenalidomide, idelalisib |
| NCT02365532 Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults | Long QT Syndrome | P1 | Completed | 60 | RCT, Double-blind | GS-6615, Placebo to match GS-6615, Placebo to match dofetilide, Dofetilide |
| NCT02400307 Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal Function | HIV | P1 | Completed | 19 | Open-label | Bictegravir |
| NCT03954704 Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Terminated | 22 | Open-label | Dalutrafusp alfa, mFOLFOX6 Regimen, Dalutrafusp alfa |
| NCT00002206 A Study of Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Been Treated With Anti-HIV Drugs | HIV Infections | P1 | Completed | 45 | Double-blind | Adefovir dipivoxil |
| NCT01270698 Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer | Metastatic Colorectal Cancer | P1 | Completed | 26 | Open-label | IMMU-130 |
| NCT00499967 Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts | Genital Warts | P1 | Completed | 202 | RCT, Double-blind | GS-9191 ointment, GS-9191, Placebo |
| NCT00002128 Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected Patients | HIV Infections | P1 | Completed | 15 | — | Adefovir dipivoxil |
| NCT02654002 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics | Nonalcoholic Steatohepatitis (NASH) | P1 | Completed | 120 | RCT, Double-blind | Cilofexor, Placebo |
| NCT02876796 Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects | PD Effects of GS-0976 (NDI-010976) on Fractional DNL | P1 | Completed | 30 | RCT, Double-blind | GS-0976, Placebo |
| NCT02402452 Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment | HCV Infection | P1 | Completed | 20 | Open-label | Voxilaprevir |
| NCT02258555 Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma | Follicular Lymphoma, Chronic Lymphocytic Leukemia | P1 | Terminated | 7 | Open-label | GS-9901 |
| NCT03060447 Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers | HIV-1 Infection | P1 | Completed | 25 | RCT, Double-blind | Vesatolimod, Placebo, ART |
| NCT04049617 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Terminated | 18 | Open-label | Evixapodlin |
| NCT00002180 A Study of PMPA in HIV-Infected Patients | HIV Infections | P1 | Completed | — | Double-blind | Tenofovir |
| NCT02521376 Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function | Oncology | P1 | Completed | 56 | Open-label | Entospletinib |
| NCT01793649 A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects | Cystic Fibrosis, Chronic Obstructive Pulmonary Disease | P1 | Terminated | 7 | RCT, Double-blind | GS-5737 |
| NCT02242045 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) | Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma | P1 | Completed | 6 | Open-label | Idelalisib |
| NCT03248479 Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies | Hematological Malignancies | P1 | Terminated | 258 | Open-label | Magrolimab, Azacitidine |
| NCT02357602 Dose Proportionality of TFV-DP After a Single Dose of GS-7340 in Women | Healthy | P1 | Completed | 24 | Open-label | GS-7340 |
| NCT00999531 A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 in Healthy Volunteers | Cystic Fibrosis, Mucociliary Clearance | P1 | Completed | 24 | RCT, Double-blind | GS-9411, Placebo |
| NCT02533427 Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol | HCV Infection | P1 | Completed | 15 | Open-label | SOF/VEL/VOX, VOX, Norgestimate/ethinyl estradiol |
| NCT01675973 A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine | Severe Renal Impairment | P1 | Terminated | 4 | Open-label | RANEXA |
| NCT01849003 Study of the Effect of GS-6615 in Subjects With LQT-3 | Long QT Syndrome | P1 | Completed | 24 | Open-label | GS-6615 |
| NCT05169944 Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors | Brain Cancer, Malignant Brain Tumor | P1 | Completed | 13 | Open-label | Magrolimab |
| NCT04747470 Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Terminated | 13 | Open-label | GS-3583, Zimberelimab, Cisplatin, Carboplatin, 5-Fluorouracil, Docetaxel |
| NCT02457598 Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies | B-cell Malignancies | P1 | Terminated | 203 | Open-label | Tirabrutinib, Idelalisib, Entospletinib, Obinutuzumab |
| NCT01816646 Intravesical Cidofovir for Hemorrhagic Cystitis | Blood And Marrow Transplantation | P1 | Completed | 6 | Open-label | Cidofovir, Probenecid |
| NCT04789408 Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia | P1 | Terminated | 15 | Open-label | Cyclophosphamide, Fludarabine, KITE-222 |
| NCT00002115 A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of 9-(2-Phosphonylmethoxyethyl)Adenine ( PMEA; Adefovir ) in Patients With Advanced HIV Disease. | HIV Infections | P1 | Completed | 20 | — | Adefovir |
| NCT05489406 Relative Bioavailability Study to Investigate a Potential Interaction Between DTG DT and F/TAF TOS. | Hiv | P1 | Completed | 16 | RCT, Open-label | DTG DT (6 x 5 mg), F/TAF TOS (3 x 60/7.5 mg) |
| NCT01779505 A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GS-4774 (GI-13020) at Various Dose Levels and Regimens in Healthy Adults | Healthy Volunteers | P1 | Completed | 60 | RCT, Open-label | GS-4774 |
| NCT07115368 Study of GS-1219 in Participants With HIV-1 | HIV-1-infection | P1 | Terminated | 4 | Open-label | GS-1219, BVY, Standard of Care |
| NCT01025713 A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF) | Cystic Fibrosis, Mucociliary Clearance | P1 | Withdrawn | — | RCT, Double-blind | GS-9411, Placebo |
| NCT01362231 A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | P1 | Completed | 48 | RCT, Open-label | GS-6624 |
| NCT02808312 Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function | Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC) | P1 | Completed | 57 | Open-label | Cilofexor |
| NCT02275065 Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants | HIV-1 Infection | P1 | Completed | 23 | RCT, Double-blind | Bictegravir, Placebo |
| NCT03369002 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects | Hepatic Impairment | P1 | Completed | 32 | Open-label | seladelpar |
| NCT01831427 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis | Ulcerative Colitis | P1 | Completed | 74 | RCT, Double-blind | Andecaliximab, Placebo to match Andecaliximab |
| NCT01644799 Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma | Recurrent Follicular Lymphoma | P1 | Completed | 8 | Open-label | idelalisib, lenalidomide |
| NCT03151057 Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies | B Cells-Tumors, B Cell Chronic Lymphocytic Leukemia | P1 | Terminated | 16 | RCT, Double-blind | Idelalisib 100 MG, Placebo Oral Tablet |
| NCT00800579 Trial to Assess the Safety, Tolerability and Pharmacokinetics of GS-9411 in Healthy Male Volunteers | Cystic Fibrosis | P1 | Completed | 12 | RCT, Double-blind | GS-9411, Placebo |
| NCT04809623 Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE) | Cutaneous Lupus Erythematosus | P1 | Terminated | 3 | RCT, Double-blind | Edecesertib, Placebo, Standard of Care |
| NCT03318861 Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Multiple Myeloma | P1 | Terminated | 17 | Open-label | Cyclophosphamide, Fludarabine |
| NCT01841489 A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics | Chronic Lymphocytic Leukemia | P1 | Completed | 56 | RCT, Open-label | Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F, Treatment G, Treatment H, Treatment I, Treatment J |
| NCT00002327 The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients | HIV Infections, Condyloma Acuminata | P1 | Completed | 40 | — | Cidofovir |
| NCT01193478 A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C | HCV Infection | P1 | Completed | 71 | RCT, Double-blind | GS-5885, Placebo, GS-5885, Placebo, GS-5885, Placebo, GS-5885, Placebo, GS-5885, Placebo, GS-5885, Placebo |
| NCT02678338 CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies | Acute Myeloid Leukemia, Myelodysplastic Syndrome | P1 | Completed | 20 | Open-label | Hu5F9-G4 |
| NCT01273402 Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | P1 | Withdrawn | — | Open-label | TF2/IMP288 |
| NCT03624036 Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma | P1 | Terminated | 16 | Open-label | brexucabtagene autoleucel, Fludarabine, Cyclophosphamide |
| NCT02077465 Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease | P1 | Completed | 11 | RCT, Double-blind | Andecaliximab, Placebo to match Andecaliximab |
| NCT01590641 A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B | Hepatitis B, HBV | P1 | Completed | 49 | RCT, Double-blind | Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts |
| NCT01845740 Phase Ib Study of SC Milatuzumab in SLE | Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid | P1 | Completed | 22 | RCT, Double-blind | milatuzumab, Placebo |
| NCT04811040 Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection | HIV-1 Infection | P1 | Completed | 32 | RCT, Double-blind | Oral Lenacapavir, Subcutaneous Lenacapavir, Teropavimab, Zinlirvimab |
| NCT00002346 The Safety and Effectiveness of Bis-POM PMEA in HIV-Infected Patients | HIV Infections | P1 | Completed | 36 | Double-blind | Adefovir dipivoxil |
| NCT04025216 A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | Non-Small Cell Lung Cancer, Ovarian Cancer | P1 | Terminated | 16 | Open-label | CART-TnMUC1, Cyclophosphamide, Fludarabine |
| NCT03399448 NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) | Multiple Myeloma, Melanoma | P1 | Terminated | 3 | Open-label | NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1, Cyclophosphamide, Fludarabine |
| NCT02626026 Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA) | Rheumatoid Arthritis | P1 | Completed | 42 | RCT, Double-blind | Tirabrutinib, Placebo |
| NCT02959138 Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function | Inflammatory Disease | P1 | Completed | 36 | Open-label | Lanraplenib. |
| NCT02436135 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease | Myelofibrosis | P1 | Terminated | 10 | Open-label | Idelalisib, Ruxolitinib |
| NCT02441829 Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function | Long QT Syndrome | P1 | Completed | 55 | Open-label | Eleclazine |
| NCT03912831 Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers | Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer | P1 | Terminated | 8 | Open-label | KITE-439, Cyclophosphamide, Fludarabine, Interleukin-2 |
| NCT06165614 Artesunate Pessaries (Vaginal Inserts) for Cervical Precancer in Kenya | Cervix Cancer, Cervix Neoplasm | P1 | Completed | 17 | Open-label | Artesunate pessary |
| NCT02538614 Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia (CLL) | P1 | Terminated | 2 | Open-label | Idelalisib, BI 836826 |
| NCT02619604 A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | N/A | Completed | 50 | Open-label | — |
| NCT03693040 Digital Health Feedback System (DHFS) for Longitudinal Monitoring of ARVs Used in HIV Pre-exposure Prophylaxis (PrEP) | HIV Prevention | N/A | Unknown | 100 | Open-label | — |
| NCT06607393 CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3] | Metastatic Nonsmall Cell Lung Cancer | Completed | 851 | — | Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin | |
| NCT01236261 Prospective Population Study on Candidemia in Spain | Fungemia | Completed | 730 | — | — | |
| NCT03405194 Same-Day Treatment With Genvoya vs. EFV/TDF/3TC | HIV/AIDS | N/A | Withdrawn | — | RCT, Open-label | Elvitegravir, Cobicistat, TAF, FTC, Efavirenz, TDF, and 3TC |
| NCT06585189 CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4] | Metastatic Non Small Cell Lung Cancer | Completed | 304 | — | Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin | |
| NCT06607601 CARE Initiative: Real-world Emulation of the PALOMA-2 Trial | Metastatic Breast Cancer | Completed | 724 | — | Palbociclib, Letrozole | |
| NCT03752658 TAF Real World Study for Universal Effectiveness | Chronic Hepatitis b | Unknown | 500 | — | Tenofovir Alafenamide | |
| NCT03581383 Community Access, Retention in Care, and Engagement for Hepatitis C Treatment | Hepatitis C | N/A | Completed | 657 | RCT, Open-label | — |
| NCT05175339 Long-term Impact in Intensive Care Survivors of Coronavirus Disease (COVID-19) | COVID-19 | Completed | 26 | — | — | |
| NCT03772002 Hepatitis C Surveillance With Linkage to Care of Patients From Non-ID Departments in Jiangsu | Hepatitis C, Chronic | N/A | Unknown | 600 | Open-label | — |
| NCT00002181 Cidofovir as a Treatment for Herpes Simplex in Patients With AIDS | Herpes Simplex, HIV Infections | N/A | Completed | — | Open-label | Cidofovir |
| NCT02510300 A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials | Hepatitis C Virus Infection | Terminated | 461 | — | Sofosbuvir (SOF), Ledipasvir/Sofosbuvir (LDV/SOF), Sofosbuvir/Velpatasvir (SOF/VEL), Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) | |
| NCT05725109 Hepatitis C Diagnosis to Treatment Management | Hepatitis C | Completed | 1,063 | — | — | |
| NCT02591277 Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection | Hepatitis C | Completed | 3,294 | — | Harvoni | |
| NCT02247934 Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC) | Primary Sclerosing Cholangitis | Completed | 26 | — | — | |
| NCT05978232 NAVAH Impact on Radiation Therapy Completion in Black Breast & Prostate Cancer Patients | Breast Cancer, Prostate Cancer | N/A | Completed | 30 | Open-label | — |
| NCT04868864 The Ontario Multi-Regional Hospital COVID-19 Registry (COREG)- Recovery Trajectory Sub-study | COVID-19 Pneumonia, Sars-CoV-2 Infection | Unknown | 200 | — | — | |
| NCT04847622 Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir. | Covid19 | Completed | 451 | — | Remdesivir | |
| NCT05627466 US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Relapsed/Refractory Acute Myeloid Leukemia | NO_LONGER_AVAILABLE | — | — | Magrolimab | |
| NCT00042393 An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options | Chronic Hepatitis B | APPROVED_FOR_MARKETING | — | — | Adefovir Dipivoxil | |
| NCT01850212 A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects | HIV Infections | Completed | 476 | — | — | |
| NCT02427204 Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related Quality | Hepatitis C Infection | Completed | 150 | — | — | |
| NCT07449091 Adaptability of an Undetectable = Untransmissible Model for HBV | Chronic Hepatitis b, Viremia | Not Yet Recruiting | 55 | — | — | |
| NCT01590615 Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy | Hepatitis B | Completed | 54 | — | Anti-HBV nucleoside/nucleotide therapy | |
| NCT01779518 Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C | Post-transplant Hepatitis C | APPROVED_FOR_MARKETING | — | — | Sofosbuvir, Ribavirin, Pegylated Interferon | |
| NCT01072669 Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet | Ischemia | N/A | Completed | 20 | RCT, Double-blind | ambrisentan |
| NCT01902472 A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP) | HIV | Completed | 172 | — | — | |
| NCT07379658 Long-Acting Injectable HIV PrEP PROs | HIV Pre-exposure Prophylaxis | Not Yet Recruiting | 128 | — | — | |
| NCT03701438 Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib | B-cell Malignancies | Terminated | 2 | — | Influenza Vaccine | |
| NCT03897725 Evaluating The Acceptability and Uptake of Pre-Exposure Prophylaxis (PrEP) for Adolescent Women in The Deep South | Adolescent Behavior, HIV/AIDS | N/A | Withdrawn | — | RCT, Open-label | — |
| NCT03049176 The Impact and Cost-effectiveness of Safer Conception Strategies for HIV-discordant Couples (SAFER) | HIV Infections | Completed | 46 | — | PrEP (Truvada), Antiretrovirals | |
| NCT03387397 Assessing Differential Adherence to Medications and Quality of Life Among People Living With HIV and Comorbidities | HIV Infection Primary | Completed | 170 | — | — | |
| NCT06539052 MIGrant Reflex Test HDV (MIGRED) Project | Hepatitis D Virus Infection | Not Yet Recruiting | 7,500 | — | — | |
| NCT00158704 Continued Access Study of Adefovir Dipivoxil (ADV) for Patients w/Chronic HBV Infection. | Hepatitis B | N/A | Terminated | 400 | Open-label | Hepsera |
| NCT01754428 Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of Age | Respiratory Syncytial Virus Infections | Completed | 2,432 | — | — | |
| NCT05319613 Reducing Disparities in Rural HIV Prevention | HIV Infections, Sexually Transmitted Infections | N/A | Completed | 69 | Open-label | — |
| NCT00499720 Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection | Cystic Fibrosis, Pseudomonas Aeruginosa Airway Infection | APPROVED_FOR_MARKETING | — | — | Aztreonam Lysine for Inhalation | |
| NCT01505179 The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction | Heart Failure With Preserved Ejection Fraction | N/A | Completed | 10 | RCT, Double-blind | Ranolazine, Placebo |
| NCT04560556 Linking Persons With HIV, Discharged From Jail, With Community Care | Human Immunodeficiency Virus | Completed | 122 | — | — | |
| NCT00002161 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Adefovir Dipivoxil When Added to Standard Antiretroviral Therapy for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 200/mm3 | HIV Infections | N/A | Completed | 400 | Double-blind | Adefovir dipivoxil |
| NCT01646541 Symptomatic Pulmonary Arterial Hypertension After Mitral Valve Surgery | Pulmonary Hypertension, Mitral Valve Disease | Completed | 100 | — | — | |
| NCT02179710 Cystic Fibrosis Treatment Adherence Cayston Proof-of-Concept Pilot Study | Cystic Fibrosis | Completed | 18 | — | — | |
| NCT03877536 Antiretroviral Therapy for Acute HIV Infection | HIV Infections | N/A | Withdrawn | — | Open-label | Genvoya 150Mg-150Mg-200Mg-10Mg Tablet |
| NCT06148610 Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients' Quality of Life and Support | Hematologic Diseases, Bone Marrow Transplantation | Unknown | 170 | — | — | |
| NCT07053527 Welcome to PrEP School Utilizing Peer Educators to Improve Uptake of Preexposure Prophylaxis for HIV at an HBCU | HIV Prevention Program | N/A | By Invite | 123 | Open-label | — |
| NCT03038763 Vertical Transmission of Hepatitis C in Adult Children of Female Baby Boomers | Hepatitis C, Hepatitis C, Chronic | Completed | 100 | — | — | |
| NCT05401136 Evaluating the Chain of Addiction Care (CAC) | Hepatitis C, Chronic, Substance Use Disorders | Unknown | 1,000 | — | — | |
| NCT02573376 Antiviral Pharmacology and Adherence in Drug Users | HEPATITIS C, Virus, Human Immunodeficiency | N/A | Completed | 73 | RCT, Open-label | — |
| NCT03498625 Crohn's Disease Endoscopic REmission Definition in an Objective Way | CD | N/A | Completed | 240 | Open-label | — |
| NCT02136511 Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia (CLL) | APPROVED_FOR_MARKETING | — | — | Idelalisib, Rituximab | |
| NCT01457768 A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response | Hepatitis C, Chronic | Completed | 570 | — | — | |
| NCT04286347 HCV, HBV, HIV Testing During Consultation With Anesthesiologist | HCV, HBV | N/A | Terminated | 363 | Open-label | — |
| NCT02292706 A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection | Hepatitis C Virus Infection | Terminated | 1,609 | — | Sofosbuvir, Ribavirin, LDV/SOF, SOF/VEL, SOF/VEL/VOX, Other SOF-Based Regimen | |
| NCT02258581 Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection | Chronic Hepatitis B | Terminated | 241 | — | GS-4774, GS-9620, Tenofovir disoproxil fumarate (TDF) | |
| NCT00989807 Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis | Cystic Fibrosis, Pseudomonas Aeruginosa | APPROVED_FOR_MARKETING | — | — | Aztreonam lysine | |
| NCT05369507 Eliminating HCV in Rural South Carolina Utilizing NP Led Mobile Clinics and Virtual Care Coordination | Hepatitis C, Substance Use Disorders | N/A | Completed | 146 | RCT, Single-blind | — |
| NCT05087927 Study for IFE4PrEP Intervention on PrEP Uptake by Southern African American Women | HIV Prevention | Completed | 31 | — | — | |
| NCT05481216 HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV | HIV-1-infection, COVID-19 | Completed | 2,598 | — | — | |
| NCT04756193 Evaluate Long Term Cardiovascular and Pulmonary Complications After COVID-19 With Point of Care Ultrasound | Covid19, Echocardiography | Completed | 98 | — | — | |
| NCT02755402 Accelerated Pre-treatment Evaluation for HCV Infected Persons Who Inject Drugs | Hepatitis C, Intravenous Drug Users | N/A | Completed | 103 | Open-label | — |
| NCT02074891 Sustainable Healthcenter Implementation PrEP Pilot Study | HIV Chemoprophylaxis, HIV Preexposure Prophylaxis | Completed | 1,420 | — | coformulated TDF/FTC | |
| NCT04891445 Hepatitis C in Severe Mental Disorders: Nursing Programme | Hepatitis C, Severe Mental Disorder | N/A | Completed | 16 | RCT, Single-blind | — |
| NCT03627546 HCV Seek, Test and Rapid Treatment for Young PWID | Hepatitis C, Drug Use | N/A | Completed | 39 | RCT, Open-label | — |
| NCT01480336 The Adjunctive Ventricular Arrhythmia Suppression Trial (AVAST) Pilot | Arrhythmia | N/A | Completed | 19 | RCT, Double-blind | Amiodarone Plus Ranolazine, Amiodarone with Placebo |
| NCT01728935 Tenofovir in Asian Chronic Hepatitis B Patients | Chronic Hepatitis B | N/A | Completed | 141 | Open-label | Tenofovir disoproxil |
| NCT02783976 Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice | HCV Infection | Completed | 25 | — | Sovaldi | |
| NCT02295384 Use of Concomitant Medications in HIV-1 Infected Patients in a Large Community Practice in Sydney, Australia | HIV | Completed | 1,104 | — | — | |
| NCT00548041 Rapid HIV Testing Program in the Emergency Department | HIV Infections | N/A | Completed | 100 | Open-label | — |
| NCT05723068 Burden of Hepatitis D Virus (HDV) Infection in Italy | Chronic Hepatitis D | Completed | 515 | — | — | |
| NCT01457755 Gilead Sustained Virologic Response (SVR) Registry | Hepatitis C, Chronic | Completed | 6,625 | — | — | |
| NCT03134105 A Wearable EducAtional Intervention to REduce Angina | Angina | N/A | Withdrawn | — | RCT, Open-label | — |
| NCT07390409 ALIGN: A Non-randomised Study Delivering Injectable Lenacapavir for HIV Prevention Within a Pre-exposure Prophylaxis (PrEP) Choice Context in Cape Town, South Africa. | HIV | Not Yet Recruiting | 3,700 | — | Lenacapavir Injection, Cabotegravir (CAB) LA, Tenofovi-Emtricitabine (TDF/FTC) tablet | |
| NCT02167100 Patient Retention in HIV Medical Care in a Primary Care Practice in Australia | HIV | Completed | 1,537 | — | — | |
| NCT04610762 HCV RNA Fingerstick Assay as Useful Point of Care of Diagnostic Tool for Drug Users in Brussels | Hepatitis C, Chronic | Completed | 103 | — | — | |
| NCT02687061 Chronic Hepatitis B and C Recall Northern Holland | Hepatitis B, Hepatitis C | Unknown | 300 | — | — | |
| NCT00002142 An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS | Cytomegalovirus Retinitis, HIV Infections | N/A | Completed | 100 | Open-label | Cidofovir, Probenecid |
| NCT03153462 Axicabtagene Ciloleucel Expanded Access Study | Relapsed/Refractory Diffuse Large B Cell Lymphoma, Relapsed/Refractory Primary Mediastinal B Cell Lymphoma | APPROVED_FOR_MARKETING | — | — | Axicabtagene Ciloleucel | |
| NCT01864603 Sustainable East Africa Research in Community Health | HIV, Tuberculosis | N/A | Completed | 150,395 | RCT, Open-label | — |
| NCT07031219 HIV/HBV/HCV Triple Screening in Primary Care | HIV, HBV (Hepatitis B Virus) | N/A | Not Yet Recruiting | 50 | Open-label | — |
| NCT04519970 Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK) | Hiv | N/A | Completed | 100 | Open-label | — |
| NCT00002398 Safety and Effectiveness of Giving Adefovir (Preveon) Plus Other Anti-HIV Drugs to HIV-Infected Patients Who Have Not Responded to Other Anti-HIV Drug Combinations | HIV Infections | N/A | Completed | — | Open-label | Levocarnitine, Adefovir dipivoxil |
| NCT05690815 Express Testing and Same-day Initiation of PrEP Study | HIV Prevention | Unknown | 816 | — | Descovy | |
| NCT01066858 Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding | HIV Infections | Completed | 1,765 | — | Tenofovir disoproxil fumarate (TDF) | |
| NCT03000023 Anticipated and Perceived Benefits Following Hepatitis C Treatment | Hepatitis C, Hepatitis C, Chronic | Completed | 100 | — | — | |
| NCT02740556 Evaluation of HepCure Toolkit to Improve Harvoni Adherence | Hepatitis C, Medication Adherence | N/A | Completed | 71 | RCT, Open-label | — |
| NCT01953458 Therapeutic Option for Hepatitis B and C: a French Cohort | Viral Hepatitis B, Viral Hepatitis C | Unknown | 20,902 | — | — | |
| NCT01772121 Observational Study on Prevalence of Host and Viral Genotypes in Chronic Hepatitis B and Hepatitis C Patients in India | Hepatitis B, Hepatitis C | Completed | 1,000 | — | — | |
| NCT00002384 A Study of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS | Cytomegalovirus Retinitis, HIV Infections | N/A | Unknown | — | — | Cidofovir |
| NCT05095818 Impact of Nursing Involvement on Implementation of HIV Prevention Services | Pre-Exposure Prophylaxis (PrEP) | N/A | Completed | 440 | RCT, Double-blind | — |
| NCT03595527 Universal HIV Screening and Targeted HCV Screening in Emergency Department | Hepatitis C, Hiv | N/A | Completed | 6,350 | Open-label | — |
| NCT01319253 A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies | Cystic Fibrosis, Pseudomonas Aeruginosa | Completed | 27 | — | — |